Nifty pharma index breaks resistance at 9,355, may test 9,695

Reuters | Updated on April 01, 2019 Published on April 01, 2019

The Nifty pharma index has gained as much as 0.74 per cent to break above a resistance at 9,354.53 points.

Resistance at 9,354.53 points is identified as the 38.2 per cent Fibonacci projection level of the uptrend from its May 22, 2018, low to its September 10, 2018 high.

A close above this 38.2 per cent level may lead to a further rise to the next resistance at 9,695.07 points, the 50 per cent projection level.

The index's 20-day exponential moving average (EMA) had cut above its 200-day EMA on Friday, seen as a bullish sign. The index had cut above its parabolic SAR on Friday, which is seen as favourable.

The Trend Intensity (TI) indicator has risen to 18, suggesting the index is trending upwards, the MACD is positive and above its signal line.

The index is up 5.4 per cent this year as of the last close, with Piramal Enterprises up 16.02 per cent as the top gainer, and Lupin down 12.4 per cent as the top loser.

Published on April 01, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.